Pharmacogenetics and asthma: false hope or new dawn?
Pharmacogenetic approaches provide the opportunity to improve prescribing for asthmatic patients in order to optimise efficacy and prevent side-effects. Currently, there are comprehensive data available on the extent of genetic variation in the human genome that will further this area of research. However, less is known about the functional consequences of many of the identified polymorphisms in genes whose products may predict drug efficacy. In addition, there is a shortage of well-designed, adequately powered clinical studies in this area. This series summarises the current state of knowledge and identifies areas for further research.
Hall
I P
IP
Division of Therapeutics and Molecular Medicine, University Hospital of Nottingham, Nottingham, NG7 2UH, UK. ian.hall@nottingham.ac.uk
Sayers
I
I
D018927:Anti-Asthmatic Agents / Q000494:pharmacology; D001094:Arachidonate 5-Lipoxygenase / Q000235:genetics; D001249:Asthma / Q000175:diagnosis / Q000188:drug therapy* / Q000235:genetics*; D002986:Clinical Trials as Topic; D014644:Genetic Variation; D015894:Genome, Human; D005938:Glucocorticoids / Q000378:metabolism; D005982:Glutathione Transferase / Q000235:genetics; D006239:Haplotypes; D006801:Humans; D010597:Pharmacogenetics / Q000379:methods*; D011110:Polymorphism, Genetic; D018343:Receptors, Adrenergic, beta-2 / Q000235:genetics
D018927:Anti-Asthmatic Agents; D005938:Glucocorticoids; D018343:Receptors, Adrenergic, beta-2; D001094:Arachidonate 5-Lipoxygenase; D005982:Glutathione Transferase; C041116:leukotriene-C4 synthase